Mansour serves as the Gastroenterologist since 1997, PhD in Health Government politics in 2007; Vice president of syrian Medical syndicate since 1915 until now, President of the syrian Commission for Gastroenterology speciality 2011-2014, Council Member of the syrian medical syndicate-President of the syrian scientific committee-2010-2015,
President of the swaida Medical syndicate/2006-2010/
Council Member of the ASSLD(Arab Society for study of Liver Diseases) since 2008
Liver pathologies due to infectious agents including mainly hepatitis B and C viruses, use of some drugs or metabolic syndrome constitute real public health problems. During liver injury, cytokines play a central role in the orientation of the immune response to an effective response or not and in the establishment and maintenance of the inflammatory response, which when it becomes chronic is at the origin of dysfunctions of the liver. Our team's work focuses on studying the role of new cytokines or immunomodulatory factors (chemokines, IL-33, soluble HLA-G, etc.) and of their associated receptors in liver pathologies. We are also interested in the type of death of hepatocytes induce by cytokines such as TNF, FASL or TRAIL. We recently showed, by the use of RIPK1 kinase dead mice (Ripk1K45A) or a RIPK1 kinase activity inhibitor (Nec-1s) that blockade of RIPK1 kinase activity reduced hepatolysis during immuno-dependent hepatitis. Furthermore, using conditionally deficient mice for RIPK1 in hepatic parenchymal cells (Ripk1LPC-KO), we observed an increase in the susceptibility of mice to ConA-induced hepatitis or to the administration of PAMPs (LPS or CpG-unmethylated DNA). We have demonstrated that this hepatocyte death is apoptotic and is dependent on TNF-Î± produced mainly by activated macrophages. FasL alone or the IFNÎ³ plus TRAIL combination also sensitizes the hepatocytes of Ripk1LPC-KO mice to apoptotic death. This project is currently underway to show the role of RIPK1 in infectious hepatitis, in nonalcoholic steatohepatitis (NASH) or in drug-induced liver injury.
Chait completed his MD degree at the age of 25 from the University of California School of Medicine at San Francisco. Maxwell is a Fellow of several prestigious organizations, including the American College of Physicians, American College of Gastroenterology, American Gastroenterological Association and the American Society for Gastrointestinal Endoscopy. He is a practicing gastroenterologist on the faculty of the Columbia University College of Physicians and Surgeons. Dr. Maxwell has authored more than 37 publications in reputed journals and serves on the editorial board of the World Journal of Gastrointestinal Endoscopy.
Professor Sen-Yung Hsieh earned his MD degree from the National Yang Ming University in 1983, and obtained his PhD in Molecular Virology and Pathology from University of Pennsylvania in 1991. He received his clinical training in internal medicine, and subsequent a specialty in hepatogastroenterology in Chang Gung Memorial Hospital, Linko, Taiwan. He initially focused on the molecular virology and epidemiology of human hepatitis viruses. His team for the first time identified the zoonotic transmission of hepatitis E virus from swine to humans in 1998, which was later found in other wild and domestic animals as natural reservoirs for sporadic hepatitis E in Japan, western countries, and other parts of the world. Currently, Dr. Hsieh is interested in elucidation the molecular mechanisms involving in carcinogenesis of human hepatoma. By integration of both functional genomics and molecular and cellular biology, he has identified novel oncogenes, tumor suppressor genes, and pathways that play significant roles in oncogenesis of human hepatoma. His works have been published in J Virology, Nucleic Acid Res, PNAS, Cancer Research, Oncogene, Proteomics, J Proteome Res, Mol Cell Proteomics, J Hepatology, and Hepatology
Sen - Yung Hsieh(Research Area)
Hepatocellular carcinoma: carcinogenesis mechanisms, diagnosis, and treatments
Paul has run the Hepatitis B Foundation and Trust from 2010, taking some 10,000 HBV related calls on the National UK helpline. He has also consulted on some 500,000 HBV vaccinations and tests across Industries that work with blood risks and the ethnic communities in the UK that are endemic for HBV. He is author of websites for patients and clinicians, runs forums and publishes a range of Hepatitis Books, Booklets, Posters, Factsheets, Policy Documents and Documentaries.